Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A gut microbial signature for combination immune checkpoint blockade across cancer types

1 Mar 2024

Abstract excerpt

Immune checkpoint blockade (ICB) targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte protein 4 (CTLA-4) can induce remarkable, yet unpredictable, responses across a variety of cancers. Studies suggest that there is a relationship between a cancer patient's gut microbiota composition and clinical response to ICB; however, defining microbiome-based biomarkers that generalize across cohorts...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Gut microbiota and health
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38429524
DOI: 10.1038/s41591-024-02823-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A gut microbial signature for combination immune checkpoint blockade across cancer typesPMID 38429524Read ↗

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanomaSemantic proximity Read ↗

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeSemantic proximity Read ↗

Taxonomy-free fecal microbiome profiles enable robust prediction of immunotherapy response and toxicity in melanomaSemantic proximity Read ↗

Microbiome influencers of checkpoint blockade–associated toxicitySemantic proximity Read ↗

A review on the role of gut microbiota in immune checkpoint blockade therapy for cancerSemantic proximity Read ↗

Gut microbial structural variation associates with immune checkpoint inhibitor responseSemantic proximity Read ↗

A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Microbiome landscape and association with response to immune checkpoint inhibitors in advanced solid tumors: SCRUM-Japan MONSTAR-SCREENSemantic proximity Read ↗

Complex interactions between the microbiome and cancer immune therapySemantic proximity Read ↗

Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivorsSemantic proximity Read ↗

Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcomeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.